About this medicine

Pregabalin is relevant to psychiatry because the checked UK product has an adult generalised-anxiety-disorder licence. That is distinct from everyday anxiety and from licences in other countries.

The aim in generalised anxiety disorder is improvement in persistent anxiety and daily functioning, not simply a sedative effect. When it is used for epilepsy it is an additional treatment; the checked licence does not establish that other antiseizure medicines can be withdrawn.

What is this medicine used for?

The checked product also covers adult neuropathic pain and adjunctive treatment of partial seizures. NICE CG113 suggests considering pregabalin when an adult with GAD cannot tolerate SSRIs or SNRIs.

Which warning signs need help?

Severe breathing difficulty or inability to wake normally is an emergency. Serious allergic or blistering skin reactions and suicidal thoughts need urgent help. Dependence and withdrawal can occur at prescribed doses; physical dependence is not the same as addiction.

How do I take it safely?

The GAD SmPC describes 150–600 mg daily divided into two or three doses, starting at 150 mg daily and increasing no faster than the stated weekly steps. Renal adjustment can require much lower doses. This is product information, not an individual treatment plan.

The capsule may be taken with or without food. Use the prescribed divided-dose routine rather than taking the whole daily amount at bedtime. Kidney function can require a substantially lower total and a different frequency; haemodialysis has separate supplemental-dose instructions.

Measure the 20 mg/mL solution with the supplied dosing equipment: millilitres describe volume and milligrams describe medicine amount. Changing between products requires confirmation of both. The US Lyrica CR schedule is not a UK capsule or liquid instruction.

What side effects should I know about?

Sleepiness, dizziness, headache, nausea, swelling, blurred vision, weight gain and memory difficulties can occur. Persistent or troublesome symptoms warrant review.

Persistent visual change, increasing swelling or marked changes in concentration deserve review. Weight gain can affect diabetes management. Constipation may become more serious when another medicine, particularly an opioid, also slows bowel function.

Who needs extra care with this medicine?

Extra care is needed with respiratory disease, kidney impairment, older age or a history of problematic medicine use. These risks require individual assessment.

A previous serious allergy prevents use. Heart failure, falls and existing breathing or neurological problems can alter the balance of benefits and risks. Reduced kidney clearance is especially relevant in older people; chronological age alone does not provide the dose.

Can it affect my other medicines?

Opioids and other sedating medicines can increase respiratory-depression risk. Alcohol can add impairment. A lack of major liver-enzyme interactions does not make these combinations harmless.

The patient leaflet specifically warns that sedating combinations can lead to coma or respiratory failure, and advises avoiding alcohol. Being minimally metabolised by the liver does not protect against these additive effects. Do not combine pregabalin and gabapentin on the assumption that their similar names imply extra benefit.

What check-ups will I need?

Review treatment benefit, kidney function, sedation, swelling and signs of dependence or tolerance. Establish a stopping strategy at the outset and reassess the need for ongoing GAD treatment.

Discuss whether the medicine is losing effect, being taken for reasons other than prescribed, or becoming difficult to reduce. These are reasons for a supportive review, not blame. Dependence can occur during appropriate use; addiction involves additional problems with control and use despite harm.

What about pregnancy, breastfeeding and age?

MHRA advice describes a possible small increase in birth-abnormality risk. Discuss pregnancy planning and effective contraception; do not stop abruptly if pregnancy occurs. Breastfeeding and use below 18 need separate assessment.

The UK leaflet advises avoiding pregnancy or breastfeeding use unless the doctor advises otherwise. Observational pregnancy findings describe an association, not proof of causation in an individual. The checked UK licence does not establish efficacy or a dosing recommendation below 18.

What if I miss a dose or want to stop?

Agree a taper when treatment ends. The current SmPC gives dose-dependent minimum withdrawal examples, but some people need weeks or months; a universal one-week taper is inappropriate.

The current label’s minimum examples differ by dose: a week at 150–300 mg daily versus three weeks at 600 mg daily. They are not universal targets or a home taper. Withdrawal may require a slower, adaptable plan; report distressing symptoms rather than abruptly stopping or escalating doses.

How does it work?

Pregabalin attaches to a supporting part of calcium channels in the nervous system. Research suggests that this can change how certain chemical messages, including messages involved in pain, are released. It is related in chemical structure to GABA, a messenger that usually quiets nerve-cell activity, but it does not directly activate GABA receptors, the proteins that receive GABA’s messages. Pregabalin is not a benzodiazepine or an antidepressant.

How Brain Cells Communicate

Electrical activity in a nerve cell can open calcium channels at its nerve endings. Calcium entering the cell helps release neurotransmitters, chemical messengers that carry information to the next cell. Channels also contain supporting components that help them work and reach the right place in the membrane. One of these components is the alpha-2-delta subunit, the part to which pregabalin binds.

What is known: Calcium-channel components help regulate communication between nerve cells.

What remains uncertain: Channel activity is one part of a wider pain-processing network.

How the process works

  1. Cell activation
  2. Calcium signaling
  3. Messenger release
Calcium-channel components help regulate communication between nerve cells. Simplified illustration of the process; individual responses vary.
About this illustration

Cell activation; Calcium signaling; Messenger release. Channel activity is one part of a wider pain-processing network.

This is a simplified illustration. It does not show exactly how a medicine fits into a protein or predict a dose or response to treatment.

How the Medication Changes Signaling

In animal studies of nerve damage, pregabalin reduced the release of some messengers that help carry pain signals. Researchers think this may involve changes in how calcium channels are moved within cells or how much calcium enters. The term channel trafficking describes this movement and positioning of channels. These findings help explain possible effects on signaling, while the full mechanism in people remains incompletely understood.

What is known: Pregabalin binds to alpha-2-delta sites and changes pain-related signaling in animal studies.

What remains uncertain: The precise contribution of each observed cellular effect to human benefit is uncertain.

How the process works

  1. Pregabalin
  2. Alpha-2-delta binding
  3. Modified signaling
Pregabalin binds to alpha-2-delta sites and changes pain-related signaling in animal studies. Simplified illustration of the process; individual responses vary.
About this illustration

Pregabalin; Alpha-2-delta binding; Modified signaling. The precise contribution of each observed cellular effect to human benefit is uncertain.

This is a simplified illustration. It does not show exactly how a medicine fits into a protein or predict a dose or response to treatment.

A Closer Look at the Molecular Level

Despite that chemical resemblance, pregabalin does not directly attach to GABA-A or GABA-B, two types of GABA receptor, or activate them the way GABA does. The active pregabalin molecule is called the S-enantiomer: one of two possible mirror-image arrangements of the same atoms. It is removed mainly through the kidneys, which influences how long it remains in the body. This removal is called renal clearance.

What is known: Pregabalin does not act as GABA itself.

What remains uncertain: Shared chemical features do not make pregabalin and gabapentin directly interchangeable.

How the process works

  1. S-enantiomer
  2. Renal clearance
  3. Individual response
Pregabalin does not act as GABA itself. Simplified illustration of the process; individual responses vary.
About this illustration

S-enantiomer; Renal clearance; Individual response. Shared chemical features do not make pregabalin and gabapentin directly interchangeable.

This is a simplified illustration. It does not show exactly how a medicine fits into a protein or predict a dose or response to treatment.

How does it affect my body?

Drowsiness, dizziness and blurred vision can affect coordination and driving. Weight gain and swelling also matter when assessing benefit and tolerability.

How does my body process it?

Pregabalin is largely excreted unchanged by the kidneys. Impaired kidney function requires an adjusted regimen rather than simply using the usual adult dose.

How do treatment options differ?

Pregabalin and gabapentin are related medicines, but the checked gabapentin product has no anxiety indication. They should not be treated as interchangeable prescriptions.

A closer look at the science

It binds the alpha-2-delta auxiliary subunit of voltage-gated calcium channels. Being a chemical analogue of GABA does not mean it works by directly replacing GABA.

Pregabalin is the S-enantiomer of an amino-acid-related small molecule. It resembles GABA structurally but does not bind directly to GABA or benzodiazepine receptors.

Chemical formula: C8H17NO2

The parent molecule contains eight carbon, seventeen hydrogen, one nitrogen, and two oxygen atoms. The stereochemical mark in the drawing identifies the particular spatial arrangement used as pregabalin, rather than an unspecified mixture.

PubChem two-dimensional structure of pregabalin, CID 5486971, with its specified S stereochemistry.
NCBI PubChem CID 5486971: Pregabalin parent compound. Lines indicate bonds; unlabeled corners indicate carbon and many hydrogens are omitted. Not a receptor-binding pose.

Parent molecule connectivity; no product release rate, clinical response or dose equivalence follows from this drawing.

How was this medicine developed?

In January 2026 the MHRA announced stronger warnings about dependence, addiction, tolerance and withdrawal for gabapentinoids. This is a UK safety update, not an FDA boxed-warning classification.

Sources and References

  1. Lyrica 75 mg hard capsules: SmPC, sections 4–5

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  2. Lyrica 25–300 mg capsules: patient leaflet, sections 1–4

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  3. Lyrica 20 mg/ml oral solution: SmPC, sections 2 and 4

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  4. Side effects of pregabalin

    Scope: NHS website for England — general medicine education, not a four-nation service pathway.

  5. Pregabalin: reports of severe respiratory depression

    Scope: United Kingdom.

  6. Pregabalin and risks in pregnancy

    Scope: United Kingdom.

  7. Improving information supplied with gabapentinoids, benzodiazepines and z-drugs (8 January 2026)

    Scope: United Kingdom.

  8. GAD and panic disorder in adults: CG113 recommendation 1.2.25

    Scope: England guidance; applicability or adoption in other UK nations requires separate consideration.

  9. Neurontin 100 mg capsules: SmPC, section 4.1

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  10. Lyrica capsules and oral solution: current prescribing information
  11. Lyrica: FDA prescribing information, April 2025
  12. Pregabalin: verified neutral parent, PubChem CID 5486971

Shared scientific background. Some references are US product pharmacology or international chemical records; UK product details and prescribing information are verified separately.

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top